Identification

Name
Fludeoxyglucose F-18
Accession Number
DB09502  (DB09150)
Type
Small Molecule
Groups
Approved
Description

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.

Structure
Thumb
Synonyms
  • (18F)-FDG
  • 18-F FDG
  • 18F-FDG
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F 18
  • Fludeoxyglucose, F-18
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fludeoxyglucose F18Injection300 mCi/mLIntravenousFeinstein Institute For Medical Research2005-08-19Not applicableUs
Fludeoxyglucose F18Injection400 mCi/mLIntravenousFeinstein Institute For Medical Research2005-08-19Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fludeoxyglucose F 18Injection, solution100 mCi/mLIntravenousHamamatsu/Queen?S Pet Imaging Center, Llc2011-11-14Not applicableUs
Fludeoxyglucose F 18Injection, solution300 mCi/mLIntravenousTriad Isotopes, Inc.2010-11-20Not applicableUs
Fludeoxyglucose F 18Injection, solution300 mCi/mLIntravenousChildren's Hospital Of Michigan2014-11-12Not applicableUs
Fludeoxyglucose F 18Injection, solution300 mCi/mLIntravenousMassachusetts General Hospital2011-10-30Not applicableUs
Fludeoxyglucose F 18Injection300 mCi/mLIntravenousCentre For Probe Development And Commercialization2011-12-01Not applicableUs
Fludeoxyglucose F 18Injection300 mCi/mLIntravenousThe University Of Utah Dba Cyclotron Radiochemistry Lab Huntsman Cancer Institute2013-11-01Not applicableUs
Fludeoxyglucose F 18Injection500 mCi/mLIntravenousHot Shots Nm, Llc Dba Midwest Positron Technology, Lc2014-08-24Not applicableUs
Fludeoxyglucose F 18Injection500 mCi/mLIntravenousSpectron Mrc, Llc2015-04-24Not applicableUs
Fludeoxyglucose F 18Injection40 mCi/mLIntravenousUniversity Of California, Los Angeles2013-06-27Not applicableUs
Fludeoxyglucose F 18Injection240 mCi/mLIntravenousMayo Clinic2013-08-05Not applicableUs
Categories
UNII
0Z5B2CJX4D
CAS number
63503-12-8
Weight
Average: 181.15
Monoisotopic: 181.061586121
Chemical Formula
C6H11FO5
InChI Key
AOYNUTHNTBLRMT-MXWOLSILSA-N
InChI
InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1/i7-1
IUPAC Name
(2R,3S,4R,5R)-2-(¹⁸F)fluoro-3,4,5,6-tetrahydroxyhexanal
SMILES

Pharmacology

Indication

The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism. Fludeoxyglucose F 18 Injection is indicated in positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer.

Structured Indications
Pharmacodynamics

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F 18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in the activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity or, (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F 18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F 18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F 18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F 18 accumulates in the myocyte and can be detected with PET imaging. Normally, the brain relies on anaerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic.

Mechanism of action

Fludeoxyglucose F 18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18F] FDG-6- phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F 18 reflect a balance involving glucose transporter, hexokinase and glucose-6- phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F 18 transport and phosphorylation (expressed as the “lumped constant” ratio), Fludeoxyglucose F 18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F 18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F 18 reflect greater than normal rates of glucose metabolism.

Absorption

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration.

Volume of distribution

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration.

Protein binding

The extent of binding of Fludeoxyglucose F 18 to plasma proteins is not known.

Metabolism

Fludeoxyglucose F 18 is transported into cells and phosphorylated to [18F]-FDG-6-phosphate at a rate proportional to the rate of glucose utilization within that tissue. [18F]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[18F] fluoro-6-phospho-Dmannose ([18F]FDM-6-phosphate). Fludeoxyglucose F 18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of C1DG are presumed to be similar to Fludeoxyglucose F 18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (C1DG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, C1DG, and ClDM) presumably leave cells by passive diffusion.

Route of elimination

Fludeoxyglucose F 18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine.

Half life

10-13 minutes

Clearance

Fludeoxyglucose F 18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours

Toxicity

Overdoses of Fludeoxyglucose F 18 Injection have not been reported.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Tragardh M, Moller N, Sorensen M: Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects. J Nucl Med. 2015 Sep;56(9):1366-71. doi: 10.2967/jnumed.115.154211. Epub 2015 Jul 9. [PubMed:26159590]
  2. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL: Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol. 2005 May;62(5):721-8. [PubMed:15883258]
  3. Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, Savoiardo M, Caraceni T, Fazio F: Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. Arch Neurol. 1995 Feb;52(2):179-85. [PubMed:7848128]
  4. FDA Label [Link]
  5. Wikipedia [Link]
External Links
ChemSpider
61878
ChEBI
49136
ChEMBL
CHEMBL1808698
ATC Codes
V09IX04 — Fludeoxyglucose (18f)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticUnspecified Adult Solid Tumor, Protocol Specific1
0RecruitingDiagnosticAutoimmune Diseases1
0RecruitingDiagnosticGlioblastomas / Malignant Neoplasms, Brain / Malignant Neoplasms, Central Nervous System / Malignant Neoplasms, Eye1
1Not Yet RecruitingScreeningUterine Cervical Neoplasms1
1RecruitingNot AvailableChronic Lung Diseases1
1RecruitingDiagnosticHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Metastatic Malignant Neoplasm in the Bone1
1RecruitingDiagnosticLeukemias1
1RecruitingScreeningMelanoma1
1TerminatedTreatmentAdenocarcinomas / Esophageal Cancers / Neoplasms, Esophageal / Squamous Cell Carcinoma (SCC)1
1TerminatedTreatmentMalignant Tumor of Peritoneum / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor1
1, 2Not Yet RecruitingDiagnosticPulmonary Hypertension (PH)1
1, 2RecruitingDiagnosticAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Male Breast Cancer / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adult Brain Tumor / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Hypopharyngeal Cancer / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Laryngeal Cancer / Recurrent Lip and Oral Cavity Cancer / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Nasopharyngeal Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Oropharyngeal Cancer / Recurrent Pancreatic Cancer / Recurrent Paranasal Sinus and Nasal Cavity Cancer / Recurrent Rectal Cancer / Recurrent Renal Cell Cancer / Recurrent Salivary Gland Cancer / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Stage IV Renal Cell Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVA Salivary Gland Cancer / Stage IVB Colon Cancer / Stage IVB Salivary Gland Cancer / Stage IVC Salivary Gland Cancer / Tongue Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
2Active Not RecruitingDiagnosticPulmonary Hypertension (PH)1
2Active Not RecruitingTreatmentStage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2CompletedDiagnosticAlzheimer's Disease (AD) / Frontotemporal Dementia1
2CompletedDiagnosticParkinson's Disease (PD)1
2CompletedTreatmentHippel-Lindau Disease / Renal Cancers1
2CompletedTreatmentSarcomas1
2RecruitingDiagnosticJoint Prosthesis1
2RecruitingDiagnosticSarcoidosis1
2RecruitingDiagnosticUrinary Bladder Neoplasms1
2RecruitingTreatmentEpendymomas1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2, 3WithdrawnDiagnosticHead and Neck Carcinoma1
3CompletedTreatmentMyocardial Ischemia1
3Unknown StatusTreatmentSevere Sepsis1
4CompletedDiagnosticPositron-Emission Tomography and Cone-Beam Computed Tomography1
4RecruitingTreatmentAsthma Bronchial1
Not AvailableActive Not RecruitingDiagnosticAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
Not AvailableActive Not RecruitingDiagnosticPatients With Idiopathic Dilated Cardiomyopathy1
Not AvailableCompletedNot AvailableCerebrovascular Disorders / Epilepsies1
Not AvailableCompletedNot AvailableLung Cancers1
Not AvailableCompletedDiagnosticKidney (Renal Cell) Cancer / Neoplasms, Kidney / Renal Cell Adenocarcinoma1
Not AvailableCompletedDiagnosticMalignant Neoplasm of Pancreas1
Not AvailableCompletedTreatmentRectum Cancer1
Not AvailableEnrolling by InvitationDiagnosticEstrogen Receptor Positive / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
Not AvailableNot Yet RecruitingNot AvailableChronic Liver Diseases (CLD) / Hepatocellular,Carcinoma / Liver Cirrhosis1
Not AvailableRecruitingNot AvailableBone Dominant Metastatic ER+ Breast Cancer1
Not AvailableRecruitingDiagnosticHead and Neck Squamous Cell Carcinoma (HNSCC)1
Not AvailableRecruitingDiagnosticMultiple Sclerosis, Primary Progressive / Relapsing Remitting Multiple Sclerosis (RRMS) / Secondary Progressive Multiple Sclerosis (SPMS)1
Not AvailableWithdrawnNot AvailableBile Duct Carcinoma / Duodenal Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
Not AvailableWithdrawnNot AvailableThyroid Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravenous20 mCi/mL
InjectionIntravenous240 mCi/mL
InjectionIntravenous40 mCi/mL
InjectionIntravenous500 mCi/mL
Injection, solutionIntravenous100 mCi/mL
Injection, solutionIntravenous200 mCi/mL
InjectionIntravenous200 mCi/mL
InjectionIntravenous300 mCi/mL
InjectionIntravenous400 mCi/mL
Injection, solutionIntravenous.3 Ci/mL
Injection, solutionIntravenous300 mCi/mL
Injection, solutionIntravenous500 mCi/mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility139.0 mg/mLALOGPS
logP-1.8ALOGPS
logP-2.7ChemAxon
logS-0.12ALOGPS
pKa (Strongest Acidic)10.32ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity35.65 m3·mol-1ChemAxon
Polarizability15.54 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta-hydroxy aldehydes. These are organic compounds containing an aldehyde substituted with a hydroxy group on the second carbon atom.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Beta-hydroxy aldehydes
Alternative Parents
Secondary alcohols / Fluorohydrins / Polyols / Primary alcohols / Organofluorides / Organic oxides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Beta-hydroxy aldehyde / Secondary alcohol / Halohydrin / Fluorohydrin / Polyol / Organic oxide / Hydrocarbon derivative / Primary alcohol / Organofluoride / Organohalogen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
2-deoxy-2-fluoro-aldehydo-D-glucose, 2-deoxy-2-((18)F)fluoro-D-glucose (CHEBI:49136)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Mannokinase activity
Specific Function
Not Available
Gene Name
HK1
Uniprot ID
P19367
Uniprot Name
Hexokinase-1
Molecular Weight
102485.1 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Insulin-regulated facilitative glucose transporter.
Gene Name
SLC2A4
Uniprot ID
P14672
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 4
Molecular Weight
54786.79 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Hexose transmembrane transporter activity
Specific Function
Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta c...
Gene Name
SLC2A2
Uniprot ID
P11168
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 2
Molecular Weight
57488.955 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Facilitative glucose transporter that can also mediate the uptake of various other monosaccharides across the cell membrane (PubMed:9477959, PubMed:26176916). Mediates the uptake of glucose, 2-deox...
Gene Name
SLC2A3
Uniprot ID
P11169
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 3
Molecular Weight
53923.785 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Cytochalasin B-sensitive carrier. Seems to function primarily as a fructose transporter.
Gene Name
SLC2A5
Uniprot ID
P22732
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 5
Molecular Weight
54973.42 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Facilitative glucose transporter; binds cytochalasin B with low affinity.
Gene Name
SLC2A6
Uniprot ID
Q9UGQ3
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 6
Molecular Weight
54538.55 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
High-affinity transporter for glucose and fructose Does not transport galactose, 2-deoxy-d-glucose and xylose.
Gene Name
SLC2A7
Uniprot ID
Q6PXP3
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 7
Molecular Weight
55726.915 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Insulin-regulated facilitative glucose transporter. Binds cytochalasin B in a glucose-inhibitable manner. Seems to be a dual-specific sugar transporter as it is inhibitable by fructose (By similari...
Gene Name
SLC2A8
Uniprot ID
Q9NY64
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 8
Molecular Weight
50818.54 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Sugar:proton symporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A10
Uniprot ID
O95528
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 10
Molecular Weight
56910.77 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A11
Uniprot ID
Q9BYW1
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 11
Molecular Weight
53702.055 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A12
Uniprot ID
Q8TD20
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 12
Molecular Weight
66965.7 Da

Drug created on November 30, 2015 12:10 / Updated on October 02, 2017 06:16